薬物療法

Question

PubMed検索式("Breast Neoplasms/drug therapy"[MH] AND "Chemotherapy, Adjuvant"[MH] AND(("Antineoplastic Agents, Hormonal"[MH] OR

BQ1

ホルモン受容体陽性乳癌に対して、内分泌療法は有用か？

"Antineoplastic Agents, Hormonal" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR ("Estrogen
Antagonists"[MH] OR "Estrogen Antagonists" [PA]) OR "Gonadotropin-Releasing Hormone"[MH] OR "Tamoxifen"[MH] OR("Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR (("Nitriles"[MH] OR "Triazoles"[MH]) AND ("2016"[DP] :"2019"[DP]))))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])タモキシフェンは子宮内膜癌（子宮BQ2体癌）発症のリスクを増加させる
か？

(("Endometrial Neoplasms"[MH] OR ("breast neoplasms"[MH] AND ("endometrial"[TIAB] OR "Endometrium"[TIAB]))) AND"tamoxifen"[MH] AND ("english"[LA] OR "japanese"[LA]) AND 2016/01/01:2021/03/31[DP]) AND (humans[MH])("Carcinoma, Intraductal, Noninfiltrating/drug therapy"[MH] OR "Breast Carcinoma In Situ/drug therapy"[MH] OR "Carcinoma,

ホルモン受容体陽性非浸潤性乳管癌
CQ1に対して乳房部分切除後の内分泌療法は推奨されるか？

Lobular/drug therapy"[MH] OR "Carcinoma, Intraductal, Noninfiltrating/drug therapy"[MH]) AND ("Neoadjuvant Therapy"[MH] OR"neoadjuvant"[TIAB] OR "preoperative"[TIAB]) AND (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal"[PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR "Tamoxifen"[MH] OR "Letrozole"[MH] OR "Anastrozole"[MH]OR "exemestane" [NM] OR ("Nitriles"[MH] OR ("Triazoles"[MH] AND ("2016"[DP] : "2018"[DP])))) AND (english[LA] OR japanese[LA])AND ("2016/01"[DP] : "2021/03"[DP])CQ2

閉経前ホルモン受容体陽性乳癌に対する術後内分泌療法として何が推奨されるか？

((("Breast Neoplasms/drug therapy"[MH]) AND ("Premenopause"[MH])) AND ("Chemotherapy, Adjuvant"[MH])) AND((((("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR ("Tamoxifen"[MH])) OR ("GonadotropinReleasing Hormone"[MH])) OR ("Receptors, Estrogen"[MH])) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA])) AND((2016/1:2021/3[DP]) AND (english[LA] OR japanese[LA])) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])Breast Neoplasms/drug therapy[MH] AND (postmenopause[MH] OR postmenopausal*[TIAB] OR postmenopause*[TIAB]) AND

CQ3

閉経後ホルモン受容体陽性乳癌に対する術後内分泌療法として何が推奨されるか？

"Chemotherapy, Adjuvant"[MH] AND (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR"Tamoxifen"[MH] OR "Receptors, Estrogen"[MH] OR ("Estrogen Antagonists"[MH] OR "Estrogen Antagonists" [PA]) OR ("Aromatase
Inhibitors"[MH] OR "Aromatase Inhibitors" [PA]) OR "Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR ("Nitriles"[MH]OR ("Triazoles"[MH] and ("2016"[DP] : "2018"[DP])))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP]) AND(Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])("Breast Neoplasms/drug therapy"[MH] AND "Chemotherapy, Adjuvant"[MH] AND (("Antineoplastic Agents, Hormonal"[MH] OR"Antineoplastic Agents, Hormonal" [PA]) OR "Tamoxifen"[MH] OR "Gonadotropin-Releasing Hormone"[MH] OR ( "Aromatase
CQ4

浸潤性乳癌に対して、術後5年間の Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] ) OR ( "Estrogen Antagonists"[MH] OR "Estrogen Antagonists" [PA] ) OR "Receptors,
内分泌療法後に内分泌療法の追加投 Estrogen"[MH] OR "Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR (("Nitriles"[MH] OR "Triazoles"[MH] ) AND
与は勧められるか？

("2016"[DP] : "2018"[DP]))) AND ("treatment duration"[TIAB] OR "treatment period"[TIAB] OR "administration period"[TIAB] OR"administration periods"[TIAB] OR "administration and dosage" [SH] OR "Drug Administration Schedule"[MH]) AND (english[LA] OR
japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])

ホルモン受容体陽性HER2陰性乳癌 (((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (Receptor, ErbB-2[MH] OR "HER2"[Tiab]) AND (("endocrine therapy"[TIAB] ORに対する術後療法として、内分泌療 "Hormone therapy"[TIAB] OR "Antineoplastic Combined Chemotherapy Protocols"[MH] OR Chemotherapy, Adjuvant[MH] OR
法にS-1を併用することは勧められ "Antineoplastic Agents"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR Fareston[TW] OR "Aromatase Inhibitors"[MH]るか？

OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW] OR Femara[TW] OR exemestane [TW] OR
Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW]) OR ("Cyclin-Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR

CQ5"palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR
cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW] OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR
pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[Supplementary Concept] OR "Alpelisib" [TW] OR PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary
Concept] OR "capivasertib" [TW] OR AZD5363[TW])) AND (Tegafur[MH] OR Oxonic Acid[MH] OR "S-1"[Tiab] OR "TS-1"[Tiab])) AND
Human [MH] AND (English[LA] OR Japanese[LA]) AND (0001[DP] : 2021/3/31[DP]))
ホルモン受容体陽性HER2陰性乳癌 (((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (Receptor, ErbB-2[MH] OR "HER2"[Tiab]) AND (Receptors, Estrogen[MH] ORに対する術後療法として、内分泌療 Receptors, Progesterone[MH] OR "Hormone receptor positive"[Tiab]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR

CQ6

法にアベマシクリブを併用すること "Antineoplastic Agents, Hormonal"[MH]) AND (abemaciclib[Tiab] OR Verzenio[Tiab] OR "Cyclin-Dependent Kinase 4"[MH] OR "Cyclinは勧められるか？

Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW])) AND
Human [MH] AND (English[LA] OR Japanese[LA]) AND (0001[DP] : 2021/3/31[DP]))(Breast neoplasms/drug therapy[MH]) AND ("Neoadjuvant Therapy"[MH] OR ("neoadjuvant"[TIAB] OR "preoperative"[TIAB])) AND

ホルモン受容体陽性HER2陰性浸潤 (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase
FRQ1性乳癌に対して術前内分泌療法は勧 Inhibitors" [PA]) OR "Tamoxifen"[MH] OR "Letrozole"[MH] OR "Anastrozole"[MH] OR "exemestane" [NM] OR(("Nitriles"[MH] OR
められるか？

"Triazoles"[MH]) AND ("2016"[DP] : "2018"[DP]))) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP]) AND(Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])(((((Breast neoplasms/therapy[MH]) AND ((Chemotherapy, Adjuvant[MH] OR ("Drug Therapy, Combination"[MH] AND
1974:1983[MHDA]) OR ("Combined Modality Therapy"[MH:NoExp] )) OR (adjuvant[Title/Abstract] OR postoperat*[Title/Abstract])))AND (((((((((("Antineoplastic Agents, Hormonal"[MH] OR ("Antineoplastic Agents"[MH:NoExp] AND 1966:1995[MHDA]) OR"Antineoplastic Agents, Hormonal" [PA]) OR ("Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA])) OR ("Tamoxifen"[MH] OR
浸潤径0.5cm以下でリンパ節転移陰 ("Stilbenes"[MH:NoExp] AND 1966:1974[MHDA]) OR ("Phenyl Ethers"[MH] AND 1974[MHDA]) OR ("Dimethylamines"[MH] AND
FRQ2性のホルモン受容体陽性乳癌に対し 1973:1974[MHDA]))) OR ("Letrozole"[MH])) OR ("Anastrozole"[MH])) OR ("exemestane" [NM])) OR ((("Nitriles"[MH]) ORて、術後内分泌療法省略は推奨され "Triazoles"[MH]) AND (("2016"[DP] : "2018"[DP])))) OR (("Gonadotropin-Releasing Hormone"[MH] OR goserelin[TIAB] OR LHRH[TIAB]
るか？

OR LH-RH[TIAB]))) OR ("Estrogen Antagonists"[MH] OR (Estrogens[MH] AND 1966:1977[MHDA]))) OR ("Receptors, Estrogen"[MH] OR(Estrogens[MH] AND 1966:1976[MHDA]) OR ("Receptors, Drug" AND 1968:1976[MHDA]) OR ("Receptors, Cell Surface"[MH] AND
1973:1976[MHDA])))) AND (((((small*[TIAB]) OR (T1a[TIAB])) OR (T1mi[TIAB] OR less[TIAB] OR microinvasi*[TIAB])) AND ((N0[TIAB]) OR (node negative[TIAB]))) OR (T1N0[TIAB]))) AND ((english[LA] OR japanese[LA]) AND ("0000"[DP] : "2021/03"[DP]))) AND((Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT]))(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW]

化学療法を行うHER2陰性の早期乳 OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined
CQ7

癌に対して、アンスラサイクリンと Modality Therapy"[mesh:noexp])) AND (Anthracyclines[MH] OR anthracyclines[TIAB] OR doxorubicin[TIAB] OR epirubicin[TIAB] OR
タキサンの順次投与は勧められる

anthracyclines[TIAB]) AND (Taxoids[MH] OR taxoids[TIAB] OR paclitaxel[TIAB] OR docetaxel[TIAB] OR nab-paclitaxel[TIAB]) AND

か？

(Meta-Analysis[PT] OR Systematic[SB] OR randomized controlled trial[PT] OR Controlled Clinical Trial [PT]) AND ("1000/01/01"[PDAT]: "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW]

化学療法を行うHER2陰性の早期乳CQ8癌に対して、TC療法は勧められるか？

OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB] OR Antineoplastic Combined Chemotherapy Protocols[MH]) AND ("Drug
Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND ((Docetaxel[MH] OR
docetaxel[TIAB]) AND (Cyclophosphamide[MH] OR cyclophosphamide[TIAB])) AND (randomized controlled trial[pt] OR controlled
clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT(animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])

化学療法を行う早期乳癌に対して、
CQ9

dose―dense化学療法は勧められるか？

(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND ("dose dense"[TIAB] OR "short interval"[TIAB]) AND (randomized controlled
trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab]
OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR
Japanese[lang])

術前化学療法で病理的完全奏効(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW]（pCR）を得られなかったHER2陰 OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined
CQ10

性早期乳癌に対する術後化学療法と Modality Therapy"[mesh:noexp])) AND (Capecitabine[MH] OR capecitabine[TIAB] OR "Ro 09-1978"[TIAB] OR Ro-09-1978[TIAB] OR
して、カペシタビンは勧められる

Ro09-1978[TIAB] OR Xeloda[TIAB]) AND (Meta-Analysis[PT] OR Systematic[SB] OR randomized controlled trial[PT] OR Controlledか？

Clinical Trial [PT]) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (Gene Expression Profiling[MH] OR Transcriptome[MH] OR

ホルモン受容体陽性HER2陰性乳癌 transcriptome*[TW] OR "Gene Expression Signature"[TIAB] OR "gene assay"[TIAB] OR 21-gene[TIAB] OR 70-gene[TIAB] OR 95CQ11に対して、多遺伝子アッセイの結果 gene[TIAB] OR PAM50[TIAB] OR "Oncotype DX"[TIAB] OR Curebest[TIAB] OR MammaPrint[TIAB]) AND ((randomized controlled
によって、術後化学療法を省略する trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab]
ことは推奨されるか？

OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("2020/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR
Japanese[lang]))(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB]) AND ("Drug

術前薬物療法を行うHER2陽性早期 Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Trastuzumab[MH] OR
CQ12

乳癌に対して、トラスツズマブにペ Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Pertuzumab[NM] OR
ルツズマブを加えることは勧められ Pertuzumab[TIAB] OR Omnitarg[TIAB] OR Perjeta[TIAB] OR RO4368451[TIAB]) AND (Meta-Analysis[PT] OR Systematic[SB] OR
るか？

randomized controlled trial[PT] OR Controlled Clinical Trial [PT]) AND ("2016/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang]
OR Japanese[lang])

術前薬物療法で病理的完全奏効(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Neoadjuvant Therapy"[Mesh] OR neoadjuvant[TIAB] OR preoperative[TW]（pCR）を得られなかったHER2陽 OR "Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined
CQ13

性早期乳癌に対する術後薬物療法と Modality Therapy"[mesh:noexp])) AND (Ado-Trastuzumab Emtansine[MH] OR "Trastuzumab Emtansine"[TIAB] OR T-DM1[TIAB] OR
して、トラスツズマブ エムタンシ

TDM1[TIAB] OR "response guide*"[TIAB] OR "Kadcyla"[TIAB]) AND (Meta-Analysis[PT] OR Systematic[SB] OR randomized controlled

ンは勧められるか？

trial[PT] OR Controlled Clinical Trial [PT]) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug

術後薬物療法を行うHER2陽性早期 Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Trastuzumab[MH] OR
CQ14

乳癌に対して、トラスツズマブにペ Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Pertuzumab[NM] OR
ルツズマブを加えることは勧められ Pertuzumab[TIAB] OR Omnitarg[TIAB] OR Perjeta[TIAB] OR RO4368451[TIAB]) AND (randomized controlled trial[pt] OR controlled
るか？

clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT(animals[mh] NOT humans [mh])) AND ("2016/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND ("Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND (Trastuzumab[MH]OR Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Taxoids[MH] OR
HER2陽性早期乳癌に対する術後薬 taxane[TIAB] OR Paclitaxel[MH] OR paclitaxel[TIAB] OR 7epiTaxol[TIAB] OR "BMS 181339"[TIAB] OR BMS-181339[TIAB] OR
FRQ3

物療法として、アンスラサイクリン BMS181339[TIAB] OR Genexol[TIAB] OR "NSC 125973"[TIAB] OR NSC125973[TIAB] OR OncoGel[TIAB] OR "PAC (Paclitaxel)"[TIAB] ORを省略したタキサンとトラスツズマ "PTX (Paclitaxel)"[TIAB]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] ORブによる併用療法は勧められるか？ clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] OR Multicenter Study[PT] OR Clinical Trial, Phase II[PT] OR
Comparative Study[PT] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang]
OR Japanese[lang])(Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND (("Chemotherapy, Adjuvant"[MH] OR adjuvant[TIAB]) AND ("Drug
高齢者のHER2陽性早期乳癌に対す Therapy"[mesh:noexp] OR "Drug Therapy"[SH] OR "Combined Modality Therapy"[mesh:noexp])) AND (Trastuzumab[MH] OR

CQ15

る術後薬物療法として、トラスツズ Trastuzumab[TIAB] OR Herceptin[TIAB] OR "MKC 454"[TIAB] OR MKC-454[TIAB] OR Tmab[TIAB]) AND (Aged[MH] or aged[TIAB] or
マブのみによる治療は勧められる

elderly[TIAB]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR clinical trialsか？

as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] NOT (animals[mh] NOT humans [mh])) AND ("1000/01/01"[PDAT] :"2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])("breast neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "triple-negative"[Title/Abstract] AND ("Immune Checkpoint

周術期トリプルネガティブ乳癌に対CQ16

して、免疫チェックポイント阻害薬は勧められるか？

Inhibitors"[MeSH Terms] OR "Immune Checkpoint Inhibitors"[Pharmacological Action] OR "checkpoint"[Text Word] OR"atezolizumab"[Text Word] OR "pembrolizumab"[Text Word]) AND (("Combined Modality Therapy"[MeSH Terms:noexp] AND"chemotherapy, adjuvant"[MeSH Terms]) OR "Neoadjuvant Therapy"[MeSH Terms] OR "surgery"[MeSH Subheading] OR("adjuvant"[Title/Abstract] OR "neoadjuvant"[Title/Abstract])) AND ("English"[Language] OR "Japanese"[Language]) AND
0001/01/01:2021/03/31[Date - Publication]

(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "triple negative"[Text Word] AND ("adjuvant"[Text Word]
OR "neoadjuvant"[Text Word] OR "Combined Modality Therapy"[MeSH Terms] OR "antineoplastic combined chemotherapy
protocols"[MeSH Terms] OR ("postoperative"[Text Word] OR "perioperative"[Text Word] OR "preoperative"[Text Word])) AND ("Platinum
Compounds"[MeSH Terms] OR ("platinum"[Text Word] OR "carboplatin"[Text Word] OR "cisplatin"[Text Word])) AND
0001/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND (("randomized controlled
CQ17

トリプルネガティブ早期乳癌に対して、プラチナ製剤は勧められるか？

trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR"clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT"humans"[MeSH Terms]))) OR (("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "triple negative"[TextWord] AND ("adjuvant"[Text Word] OR "neoadjuvant"[Text Word] OR "Combined Modality Therapy"[MeSH Terms] OR "antineoplastic
combined chemotherapy protocols"[MeSH Terms] OR ("postoperative"[Text Word] OR "perioperative"[Text Word] OR"preoperative"[Text Word])) AND ("Platinum Compounds"[MeSH Terms] OR ("platinum"[Text Word] OR "carboplatin"[Text Word] OR"cisplatin"[Text Word])) AND 0001/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND("Systematic"[Filter] OR "Meta-Analysis"[Publication Type]))(((Triple Negative Breast Neoplasms[MH] OR ("triple negative"[TIAB] AND "breast cancer*"[TIAB])) AND ("Chemotherapy,

浸潤径1㎝以下・リンパ節転移陰性 Adjuvant"[MH] OR adjuvant[TIAB])) OR ((Breast Neoplasms[MH] OR "breast cancer"[TIAB]) AND adjuvant[TIAB] AND (T1ab[TIAB] or
FRQ4のトリプルネガティブ乳癌に対し1cm[TIAB] or pT1ab[TIAB]))) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab]て、術後化学療法は勧められるか？ OR clinical trials as topic[mesh:noexp] OR randomly[tiab] OR trial[ti] OR Multicenter Study[PT] NOT (animals[mh] NOT humans [mh]))
AND ("1000/01/01"[PDAT] : "2021/03/31"[PDAT]) AND (English[lang] OR Japanese[lang])(("Breast Neoplasms/drug therapy"[MH]) AND (("BRCA1 Protein"[MH] OR "Genes, BRCA1"[MH] OR "BRCA1 protein, human" [NM]) OR
BRCA病的バリアントを有する乳癌 ( "Genes, BRCA2"[MH] OR "BRCA2 Protein"[MH] OR "BRCA2 protein, human" [NM] ))) AND ((("Chemotherapy, Adjuvant"[MH]) OR
FRQ5

患者の周術期薬物療法として何が勧 "Neoadjuvant Therapy"[MH]) OR (adjuvant[TIAB] OR neoadjuvant[TIAB] OR postoperat*[TIAB] OR preoperat*[TIAB] OR
められるか？

perioperat*[TIAB])) AND (english[LA] OR japanese[LA]) AND ("0000"[DP] : "2021/03"[DP]) AND (Systematic Review[PT] OR
systematic[SB] OR Meta-Analysis[PT])(((("Breast Neoplasms, Male/drug therapy"[MH]) OR (("Breast Neoplasms/drug therapy"[MH:NoExp] AND 0000[DP]:1994[DP]) AND("Male"[MH]))) OR ("male breast cancer"[TIAB])) AND ((("Neoadjuvant Therapy"[MH]) OR "Chemotherapy, Adjuvant"[MH]) OR(adjuvant[TIAB] OR neoadjuvant[TIAB] OR postoperat*[TIAB] OR preoperat*[TIAB] OR perioperat*[TIAB]))) AND ((((((((("Antineoplastic
FRQ6

早期男性乳癌に対する薬物療法は何が推奨されるか？

Agents" [PA] OR "Antineoplastic Agents, Hormonal" [PA] OR "Antineoplastic Agents"[MH]) OR ("Aromatase Inhibitors"[MH] OR"Aromatase Inhibitors" [PA])) OR ("Tamoxifen"[MH] OR ("Stilbenes"[MH:NoExp] AND 1966:1974[MHDA]) OR ("Phenyl Ethers"[MH] AND
1974[MHDA]) OR ("Dimethylamines"[MH] AND 1973:1974[MHDA]) OR tamoxifen[TIAB])) OR ("Letrozole"[MH] OR letrozole[TIAB])) OR("Anastrozole"[MH] OR anastrozole[TIAB])) OR ("exemestane" [NM] OR exemestane[TIAB])) OR ((("Nitriles"[MH]) OR "Triazoles"[MH])AND (("2016"[DP] : "2018"[DP])))) OR ("palbociclib" [NM] OR palbociclib[TIAB]))) AND (english[LA] OR japanese[LA]) AND("0000"[DP] : "2021/03"[DP]) AND (Systematic Review[PT] OR systematic[SB] OR Meta-Analysis[PT])breast neoplasms/drug therapy[MeSH Terms] AND ("Aged"[MeSH Terms] OR ("elderly"[Title/Abstract] OR "older*"[Title/Abstract]))

FRQ7

早期高齢者乳癌患者に対して周術期の化学療法は勧められるか？

AND ("Antineoplastic Agents"[MeSH Terms:noexp] OR "Antineoplastic Agents"[Pharmacological Action] OR "antineoplastic agents,
hormonal"[MeSH Terms] OR "chemotherapy, adjuvant"[MeSH Terms:noexp] OR "Neoadjuvant Therapy"[MeSH Terms] OR"Adjuvant"[Title/Abstract] OR "antineoplastic combined chemotherapy protocols"[MeSH Terms]) AND 2016/01/01:2021/03/31[Date Publication] AND ("English"[Language] OR "Japanese"[Language]) AND "Randomized Controlled Trial"[Publication Type]

原発乳癌に対する再発予防を目的と "breast neoplasms"[MeSH Terms] AND ("Diphosphonates"[MeSH Terms] OR "bisphosphonate*"[Title/Abstract] OR
FRQ9する術後薬物療法として骨吸収抑制 "Denosumab"[MeSH Terms] OR ("Bone Density Conservation Agents"[MeSH Terms] OR "Bone Density Conservation
薬（ビスホスホネート製剤，デノス Agents"[Pharmacological Action])) AND "early"[Title/Abstract] AND "adjuvant"[Text Word] AND ("English"[Language] ORマブ）は勧められるか？

"Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND "randomized controlled trial"[Publication Type]

閉経前ホルモン受容体陽性転移・再 (((Breast Neoplasms[MH]) AND (Premenopause[MH] OR Premenopausal [Tiab]) AND ((Ovariectomy[MH] OR "ovarian ablation"[Tiab])
BQ5

発乳癌に対して最も有用な卵巣機能 OR (Leuprolide[MH] OR Goserelin[MH] OR triptorelin[MH]))) AND "Humans"[MH] AND ("2016/01/01"[DP] : "2021/3/31"[DP]) AND
抑制方法は何か？

("English"[LA] OR "Japanese"[LA]))

閉経前ホルモン受容体陽性 HER2陰 (((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR
性転移・再発乳癌に対する一次内分 "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined
泌療法として、何が推奨されるか？ Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR
Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW]OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("CyclinCQ18

Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR
Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW]OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR
PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW])))
AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))(((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR"Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined
Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR
閉経前ホルモン受容体陽性 HER2陰CQ19

性転移・再発乳癌に対する二次以降の内分泌療法として、何が推奨されるか？

Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW]OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("CyclinDependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR
Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW]OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR
PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW])))
AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))閉経後ホルモン受容体陽性 HER2陰 (((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR
性転移・再発乳癌に対する一次内分 "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined
泌療法として、何が推奨されるか? Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR
Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW]OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("CyclinCQ20

Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR
Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW]OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR
PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW])))
AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))
閉経後ホルモン受容体陽性 HER2陰 (((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR
性転移・再発乳癌に対する一次内分 "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combined
泌療法にアロマターゼ阻害薬単剤を Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR
使用したときの二次内分泌療法とし Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW]て、何が推奨されるか?

CQ21

OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("CyclinDependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR
Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW]OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR
PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW])))
AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))閉経後ホルモン受容体陽性 HER2陰 (((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR
性転移・再発乳癌の二次内分泌療法 "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combinedとして、何が推奨されるか?

Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR
Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW]OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-

FRQ10

Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR
Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW]OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR
PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW])))
AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))PIK3CA遺伝子変異陽性ホルモン受 (((Breast Neoplasms[MH] OR "breast cancer"[Tiab]) AND (Receptors, Estrogen [MH] OR Estrogen Receptor positive[Tiab] OR
容体陽性HER2陰性転移・再発乳癌 ER+[TIAB] OR "ER positive"[TIAB]) AND (Class I Phosphatidylinositol 3-Kinases[MH] OR PIK3CA[Tiab]) AND ((Phosphoinositide-3

FRQ11に対して、PI3K阻害薬は有用か？

Kinase Inhibitors[MH] OR Phosphoinositide-3 Kinase[Tiab]) OR (Buparlisib[Tiab] OR Buparlisib[NM]) OR (alpelisib[Tiab] OR
alpelisib[NM]) OR (Ipatasertib[Tiab] OR Ipatasertib[NM]) OR (taselisib[Tiab] OR taselisib[NM]) OR (Pictilisib[Tiab] OR Pictilisib[NM])))
AND (English[LA] OR Japanese[LA]) AND (0001[DP] : 2021/3/31[DP]))

閉経後ホルモン受容体陽性 HER2陰 (((Breast Neoplasms[MH] OR "breast cancer"[tiab]) AND (advanced[TIAB] OR metastatic[TIAB] OR "Neoplasm Metastasis"[MH] OR
性転移・再発乳癌に対する三次以降 "Neoplasm Recurrence, Local"[MH]) AND ("endocrine therapy"[TIAB] OR "Hormone therapy"[TIAB] OR "Antineoplastic Combinedの内分泌療法として、何が推奨され Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[TW] OR Norvadex[TW] OR toremifene[TW] OR
るか？

Fareston[TW] OR "Aromatase Inhibitors"[MH] OR "Aromatase Inhibitors" [PA] OR anastrozole[TW] OR Arimidex[TW] OR letrozole[TW]OR Femara[TW] OR exemestane [TW] OR Aromasin [TW] OR fulvestrant[TW] OR Faslodex[TW] OR MONARCH[Tiab]) AND (("Cyclin-

CQ22

Dependent Kinase 4"[MH] OR "Cyclin-Dependent Kinase 6"[MH] OR "palbociclib"[TW] OR Ibrance [TW] OR abemaciclib[TW] OR
Verzenio[TIAB] OR ribociclib[TW] OR LEE011[TW] OR Kisqali[TW] OR cdk[TW]) OR (everolimus[TW] OR afinitor[TW]) OR (P13K[TW]OR buparlisib[TW] OR "NVP-BKM120" [Supplementary Concept] OR pictilisib[TW] OR "2-(1H-indazol-4-yl)-6-(4methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine" [Supplementary Concept] OR "Alpelisib" [TW] OR
PIQRAY[TW]) OR ("AKT inhibitor"[TW] OR "5233705 compound" [Supplementary Concept] OR "capivasertib" [TW] OR AZD5363[TW])))
AND (English[LA] OR Japanese[LA]) AND (2016/1/1[DP] : 2021/3/31[DP]))HER2陰性転移・再発乳癌に対するBQ6

一次・二次化学療法として、アンス
ラサイクリン系薬剤は推奨されるか？

("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]
OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("Doxorubicin"[Text Word] OR"Anthracyclines"[MeSH Terms]) AND "breast neoplasms/drug therapy"[MeSH Major Topic] AND 0001/01/01:2021/03/31[Date Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("Randomized Controlled Trial"[Publication Type] OR"systematic"[Filter] OR "Meta-Analysis"[Publication Type])(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "Bevacizumab"[Text Word] AND("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR"neoplasm recurrence, local"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 2016/01/01:2021/03/31[Date -HER2陰性転移・再発乳癌に対する Publication] AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR
CQ23

一次・二次化学療法としてベバシズ "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR
マブを併用することは推奨される"randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))) OR (("Breast

か？

Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "Bevacizumab"[Text Word] AND ("advanced"[Title/Abstract] OR"metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence,
local"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 2016/01/01:2021/03/31[Date - Publication] AND("systematic"[Filter] OR "Meta-Analysis"[Publication Type]))

HER2陰性転移・再発乳癌に対するCQ24

一次・二次化学療法として経口フッ化ピリミジンは推奨されるか？

"breast neoplasms/drug therapy"[MeSH Terms] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR"recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND"fluorouracil"[MeSH Terms] AND ("first"[Title/Abstract] OR "second"[Title/Abstract]) AND ("English"[Language] OR"Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND "randomized controlled trial"[Publication Type](("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND "eribulin"[Text Word] AND ("advanced"[Title/Abstract] OR"metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence,
local"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND

HER2陰性転移・再発乳癌に対するCQ25

一次・二次化学療法としてエリブリ
ンは推奨されるか？

("systematic"[Filter] OR "Meta-Analysis"[Publication Type])) OR (("Breast Neoplasms"[MeSH Terms] OR "breast
cancer"[Title/Abstract]) AND "eribulin"[Text Word] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR"recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication] AND (("randomized controlled
trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR"clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT"humans"[MeSH Terms])))CQ26：HER2陽性転移・再発乳癌に対する一次治療として、トラスツズ
マブ＋ペルツズマブ＋タキサン併用療法は推奨されるか？
CQ27：HER2陽性転移・再発乳癌に
CQ26-28

対する一次治療として、トラスツズ
マブ エムタンシンは推奨される
か？
CQ28：HER2陽性転移・再発乳癌に対する二次治療として、トラスツズ
マブ デルクステカンは推奨されるか？

(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND ("breast neoplasms/secondary"[MeSH Terms] OR"Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metast*"[Title/Abstract] OR"advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("Ado-Trastuzumab Emtansine"[MeSH Terms] OR "Trastuzumab
Emtansine"[Title/Abstract] OR ("Trastuzumab"[MeSH Terms] AND "pertuzumab"[Supplementary Concept] AND ("Taxoids"[MeSH
Terms] OR "taxoid*"[Title/Abstract] OR "taxane*"[Title/Abstract]))) AND ("English"[Language] OR "Japanese"[Language]) AND(("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR"placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))) OR (("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract])
AND ("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH
Terms] OR "metast*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("Ado-Trastuzumab
Emtansine"[MeSH Terms] OR "Trastuzumab Emtansine"[Title/Abstract] OR ("Trastuzumab"[MeSH Terms] AND"pertuzumab"[Supplementary Concept] AND ("Taxoids"[MeSH Terms] OR "taxoid*"[Title/Abstract] OR "taxane*"[Title/Abstract]))) AND("English"[Language] OR "Japanese"[Language]) AND ("Meta-Analysis"[Publication Type] OR "Systematic"[Filter]))"breast neoplasms/drug therapy"[MeSH Terms] AND ("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH
Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR

HER2陽性転移・再発乳癌に対する "reccurren*"[Title/Abstract]) AND ("receptor, erbb 2"[MeSH Terms] OR "erbB-2"[Title/Abstract] OR "her2"[Title/Abstract] OR "herFRQ12

三次以降の治療で推奨される治療は 2"[Title/Abstract]) AND ("antibodies, monoclonal, humanized/therapeutic use"[MeSH Terms] OR "antineoplastic combined
何か？

chemotherapy protocols/therapeutic use"[MeSH Terms] OR "antineoplastic agents/therapeutic use"[MeSH Terms]) AND "Antineoplastic
Agents"[Pharmacological Action] AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR"Japanese"[Language]) AND ("Meta-Analysis"[Publication Type] OR "Systematic"[Filter])"breast neoplasms/drug therapy"[MeSH Terms] AND ("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH
Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metastatic"[Title/Abstract] OR "advanced"[Title/Abstract] OR"reccurren*"[Title/Abstract]) AND ("receptor, erbb 2"[MeSH Terms] OR "ErbB Receptors"[MeSH Terms] OR "phosphoproteins"[MeSH
Terms:noexp] OR "proto oncogene proteins"[MeSH Terms:noexp] OR "erbB-2"[Title/Abstract] OR "her2"[Title/Abstract] OR "her2"[Title/Abstract]) AND ("estrogen antagonists"[MeSH Terms] OR "estrogen antagonists"[Pharmacological Action] OR "antineoplastic
HER2陽性・ホルモン受容体陽性転 agents, hormonal"[MeSH Terms] OR "antineoplastic agents hormonal"[Pharmacological Action] OR "gonadotropin releasing
CQ29

移・再発乳癌に対して内分泌療法単 hormone"[MeSH Terms] OR "aromatase inhibitors"[MeSH Terms] OR "aromatase inhibitors"[Pharmacological Action] OR (("estrogen
独や抗HER2療法と内分泌療法併用 antagonists"[MeSH Terms] OR "estrogen antagonists"[Pharmacological Action] OR "antineoplastic agents, hormonal"[MeSH Terms] ORは勧められるか？

"antineoplastic agents hormonal"[Pharmacological Action] OR "gonadotropin releasing hormone"[MeSH Terms] OR "aromataseinhibitors"[MeSH Terms] OR "aromatase inhibitors"[Pharmacological Action]) AND "antibodies, monoclonal, humanized"[MeSH Terms])
OR "Antineoplastic Combined Chemotherapy Protocols"[MeSH Terms]) AND ("English"[Language] OR "Japanese"[Language]) AND
2016/01/01:2021/03/31[Date - Publication] AND (("randomized controlled trial"[Publication Type] OR "controlled clinical
trial"[Publication Type] OR "Randomized"[Title/Abstract] OR "Placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp]
OR "randomly"[Title/Abstract] OR "Trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))("triple negative breast neoplasms"[MeSH Terms] OR (("breast neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND

転移・再発トリプルネガティブ乳癌
CQ30に対してプラチナ製剤は勧められるか？

"triple negative"[Title/Abstract])) AND ("carboplatin"[MeSH Terms] OR "cisplatin"[MeSH Terms] OR "carboplatin"[Title/Abstract] OR"platinum"[Title/Abstract]) AND 2018/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND(("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR"placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT("animals"[MeSH Terms] NOT "humans"[MeSH Terms]))(("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND ("advanced"[Title/Abstract] OR"metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence,
local"[MeSH Terms]) AND ("atezolizumab"[Text Word] OR "pembrolizumab"[Text Word]) AND ("English"[Language] OR"Japanese"[Language]) AND 2020/01/01:2021/03/31[Date - Publication] AND (("randomized controlled trial"[Publication Type] OR
CQ31

転移・再発乳癌に対してPD-1/PDL1阻害薬は勧められるか？

"controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "clinical trials as
topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH
Terms]))) OR (("Breast Neoplasms"[MeSH Terms] OR "breast cancer"[Title/Abstract]) AND ("advanced"[Title/Abstract] OR"metastatic"[Title/Abstract] OR "recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence,
local"[MeSH Terms]) AND ("atezolizumab"[Text Word] OR "pembrolizumab"[Text Word]) AND ("English"[Language] OR"Japanese"[Language]) AND 2020/01/01:2021/03/31[Date - Publication] AND ("systematic"[Filter] OR "Meta-Analysis"[Publication
Type]))

生殖細胞系列BRCA病的バリアント
CQ32を有する進行・再発乳癌患者の薬物療法として、PARP阻害薬は推奨されるか？
生殖細胞系列BRCA病的バリアント

FRQ13を有する進行・再発乳癌患者に対してプラチナ製剤は推奨されるか？
転移・再発乳癌に対して、治癒を目FRQ14指した治療を行うことは勧められるか？

("Breast Neoplasms/drug therapy"[MH] OR "Carcinoma, Intraductal, Noninfiltrating/drug therapy"[MH] OR "Carcinoma, Ductal,
Breast/drug therapy"[MH] OR "Carcinoma, Lobular/drug therapy"[MH] OR "Breast Carcinoma In Situ/drug therapy"[MH]) AND (("BRCA1
Protein"[MH] OR "BRCA1 protein, human" [NM]) OR ("BRCA2 Protein"[MH] OR "BRCA2 protein, human" [NM]) OR ("Genes,
BRCA1"[MH] OR "Genes, BRCA2"[MH])) AND ("Poly(ADP-ribose) Polymerase Inhibitors"[MH] OR "Poly(ADP-ribose) Polymerase
Inhibitors" [PA] OR "mefuparib hydrochloride" [NM]) AND (english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])"Breast Neoplasms/drug therapy"[MH] AND (("BRCA1 Protein"[MH] OR "Genes, BRCA1"[MH] OR "BRCA1 protein, human" [NM]) OR ("Genes, BRCA2"[MH] OR "BRCA2 Protein"[MH] OR "BRCA2 protein, human" [NM] )) AND ("Platinum Compounds"[MH] OR"Carboplatin"[MH] OR ("Oxaliplatin"[MH] OR ("Organoplatinum Compounds"[MH] AND ("2016"[DP] : "2018"[DP])))) AND (english[LA]OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP])"breast neoplasms/drug therapy"[MeSH Terms] AND ("advanced"[Title/Abstract] OR "metastatic"[Title/Abstract] OR"recurren*"[Title/Abstract] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms]) AND "disease freesurvival"[MeSH Terms] AND ("tapering"[Text Word] OR "reduction*"[Title/Abstract] OR "cure"[Title/Abstract]) AND("English"[Language] OR "Japanese"[Language]) AND 0001/01/01:2021/03/31[Date - Publication]

(("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH
Terms] OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("breast neoplasms/drug
therapy"[MeSH Terms] OR "breast cancer"[Title]) AND "Maintenance"[Text Word] AND ("antineoplastic agents, hormonal"[MeSH
Terms] OR "antineoplastic agents hormonal"[Pharmacological Action] OR ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase
Inhibitors"[Pharmacological Action]) OR ("Tamoxifen"[MeSH Terms] OR "Tamoxifen"[Text Word]) OR "Fulvestrant"[Text Word] OR
転移・再発乳癌に対して、化学療法 "Bevacizumab"[Text Word]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language])) OR
FRQ15

奏効後に内分泌療法による維持療法 (("breast neoplasms/secondary"[MeSH Terms] OR "Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH
は勧められるか？

Terms] OR "metasta*"[Title/Abstract] OR "advanced"[Title/Abstract] OR "reccurren*"[Title/Abstract]) AND ("breast neoplasms/drug
therapy"[MeSH Terms] OR "breast cancer"[Title]) AND ("antineoplastic agents, hormonal"[MeSH Terms] OR "antineoplastic agentshormonal"[Pharmacological Action] OR ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase Inhibitors"[Pharmacological Action]) OR("Tamoxifen"[MeSH Terms] OR "Tamoxifen"[Text Word]) OR "Fulvestrant"[Text Word] OR "Bevacizumab"[Text Word]) AND
2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("Randomized Controlled
Trial"[Publication Type] OR "systematic"[Filter] OR "Meta-Analysis"[Publication Type]))"breast neoplasms/drug therapy"[MeSH Terms] AND ("Aged"[MeSH Terms] OR "elderly"[Title/Abstract]) AND ("Neoplasm
Metastasis"[MeSH Terms] OR "neoplasm recurrence, local"[MeSH Terms] OR "metasta*"[Title/Abstract] OR "recurren*"[Title/Abstract]

FRQ16

転移・再発高齢者乳癌に対する薬物療法として何が推奨されるか？

OR "breast neoplasms/secondary"[MeSH Terms] OR "advanced"[Title/Abstract]) AND ("Antineoplastic Agents"[MeSH Terms:noexp] OR"Antineoplastic Agents"[Pharmacological Action] OR "antineoplastic agents, hormonal"[MeSH Terms] OR "chemotherapy,
adjuvant"[MeSH Terms:noexp] OR "Adjuvant"[Title/Abstract] OR "antineoplastic combined chemotherapy protocols"[MeSH Terms])
AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language]) AND ("MetaAnalysis"[Publication Type] OR "Systematic"[Filter])

転移・再発男性乳癌に対する薬物療 (((("Breast Cancer"[Tiab] AND Men[Tiab]) OR "Male breast cancer"[Tiab] OR "Male breast carcinoma"[Tiab] OR Breast Neoplasms,
FRQ17

法は何が推奨されるか？

Male/drug therapy[MH]) AND (("Molecular Targeted Therapy"[Mesh]) OR ("endocrine therapy"[TIAB] OR "Antineoplastic Combined
Chemotherapy Protocols"[MH] OR "Antineoplastic Agents, Hormonal"[MH] OR tamoxifen[MH] OR "Aromatase Inhibitors"[MH] OR
fulvestrant[MH]))) AND ("0001/01/01"[DP] : "2021/3/31"[DP]) AND ("English"[LA] OR "Japanese"[LA]))

FRQ18

局所・領域再発切除術後に薬物療法は勧められるか？

breast neoplasms[MH] AND "neoplasm recurrence, local"[MH] AND "mastectomy"[MH] AND (chemotherapy, adjuvant[MH] OR
adjuvant[TIAB] OR postoperative[TIAB]) AND ("Drug Therapy"[MH] OR "drug therapy" [SH]) AND (english[LA] OR japanese[LA]) AND("2016/01"[DP] : "2021/03"[DP])((((("Breast Neoplasms/pathology"[MH]) AND (("Brain Neoplasms/secondary"[MH]) OR "Meningeal Neoplasms/secondary"[MH])) OR
FRQ19

乳癌脳転移および髄膜播種に抗悪性腫瘍薬は勧められるか？

((("Breast Neoplasms"[MH]) AND (("Brain Neoplasms"[MH]) OR "Meningeal Neoplasms"[MH])) AND ("Neoplasm Metastasis"[MH])))AND (("Antineoplastic Agents"[MH] OR "Antineoplastic Agents" [PA]) OR ("Drug Therapy"[MH] OR "drug therapy" [SH]))) AND((english[LA] OR japanese[LA]) AND ("2016/01"[DP] : "2021/03"[DP]))) AND ((Systematic Review[PT] OR systematic[SB] OR MetaAnalysis[PT]))(("Breast Neoplasms"[MeSH Terms] OR "Breast cancer"[Title/Abstract]) AND ("Neoplasm Metastasis"[MeSH Terms] OR "neoplasm
recurrence, local"[MeSH Terms] OR "metas*"[Title/Abstract] OR "bone neoplasms/secondary"[MeSH Terms] OR"advanced"[Title/Abstract] OR "recurren*"[Title/Abstract]) AND ("denosumab"[MeSH Terms] OR "denosumab"[Title/Abstract] OR"diphosphonates"[MeSH Terms] OR "Bisphosphonate"[Title/Abstract] OR ("Bone Density Conservation Agents"[MeSH Terms] OR "BoneDensity Conservation Agents"[Pharmacological Action])) AND ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase
Inhibitors"[Pharmacological Action] OR "aromatase"[Title/Abstract]) AND 2016/01/01:2021/03/31[Date - Publication] AND

アロマターゼ阻害薬使用患者におけ ("English"[Language] OR "Japanese"[Language]) AND ("systematic"[Filter] OR "Meta-Analysis"[Publication Type])) OR (("Breast
BQ11

る骨粗鬆症の予防・治療に骨吸収抑 Neoplasms"[MeSH Terms] OR "Breast cancer"[Title/Abstract]) AND ("Neoplasm Metastasis"[MeSH Terms] OR "neoplasm recurrence,
制薬（ビスホスホネート，デノスマ local"[MeSH Terms] OR "metas*"[Title/Abstract] OR "bone neoplasms/secondary"[MeSH Terms] OR "advanced"[Title/Abstract] ORブ）は推奨されるか？

"recurren*"[Title/Abstract]) AND ("denosumab"[MeSH Terms] OR "denosumab"[Title/Abstract] OR "diphosphonates"[MeSH Terms] OR"Bisphosphonate"[Title/Abstract] OR ("Bone Density Conservation Agents"[MeSH Terms] OR "Bone Density Conservation
Agents"[Pharmacological Action])) AND ("Aromatase Inhibitors"[MeSH Terms] OR "Aromatase Inhibitors"[Pharmacological Action] OR"aromatase"[Title/Abstract]) AND 2016/01/01:2021/03/31[Date - Publication] AND ("English"[Language] OR "Japanese"[Language])AND (("randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR"placebo"[Title/Abstract] OR "clinical trials as topic"[MeSH Terms:noexp] OR "randomly"[Title/Abstract] OR "trial"[Title]) NOT("animals"[MeSH Terms] NOT "humans"[MeSH Terms])))

乳癌診療において次世代シークエン
FRQ20

サー等を用いた遺伝子パネル検査は有用か？

((("Breast Neoplasms"[Mesh] OR "breast cancer"[TI]) AND (("Precision Medicine"[Mesh]) OR ("Molecular Targeted Therapy"[Mesh])
OR ("High-Throughput Nucleotide Sequencing"[Mesh]) OR ("next generation sequencing"[TIAB]))) NOT ("animals"[MeSH Terms] NOT"humans"[MeSH Terms]) AND (2018/01/01[PDAT] : 2021/3/31[PDAT]) AND (English[LA] OR Japanese[LA])) AND (systematic[SB] OR
Meta-Analysis[PT])乳腺悪性葉状腫瘍の遠隔転移に対し (((Breast neoplasms[MH] OR "Breast"[Tiab]) AND ("drug therapy"[TW] OR "Antineoplastic Agents"[Mesh] OR "Antineoplastic Agents"
FRQ21て薬物療法は進められるか？

[Pharmacological Action] OR chemotherapy[TW]) AND (Phyllodes Tumor[MH] OR "Phyllodes"[Tiab])) NOT (Animals[MH] NOT
Humans[MH]) AND ("2018/01/01"[DP] : "2021/3/31"[DP]) AND ("English"[LA] OR "Japanese"[LA]))